Miragen Therapeutics Inc Revenue Growth Rates (MGEN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Miragen Therapeutics Inc   (NASDAQ: MGEN)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

MGEN's Revenue Growth by Quarter and Year

Miragen Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MGEN Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.28
1st Quarter March 0.08
FY 0.36

MGENs Annual Revenue
Miragen Therapeutics Inc 's Revenue in the fiscal year 2019 $ 4.46 millions
Miragen Therapeutics Inc 's Revenue in the fiscal year 2018 $ 8.39 millions
Miragen Therapeutics Inc 's Revenue in the fiscal year 2017 $ 4.00 millions
Miragen Therapeutics Inc 's Revenue in the fiscal year 2016 $ 3.34 millions
Miragen Therapeutics Inc 's Revenue in the fiscal year 2015 $ 2.54 millions




MGEN Revenue second quarter 2020 Y/Y Growth Comment
Miragen Therapeutics Inc reported drop in Revenue in the second quarter 2020 by -67.73% to $ 0.28 millions, from the same quarter in 2019.
The fall in the second quarter 2020 Miragen Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 20.45%.

Looking into second quarter 2020 results within Medical Laboratories industry 15 other companies have achieved higher Revenue growth. While Miragen Therapeutics Inc ' s Revenue meltdown of -67.73% ranks overall at the positon no. 1221 in the second quarter 2020.


MGEN Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - - 15.14 % 202.78 %
3rd Quarter September - -54.05 % -92.26 % 939.13 %
2nd Quarter June -67.73 % 83.33 % -59.66 % 133.33 %
1st Quarter March -88.57 % -25.53 % -42.33 % 83.15 %
FY   - -59.3 % -56.03 % -

Financial Statements
Miragen Therapeutics Inc 's second quarter 2020 Revenue $ 0.28 millions MGEN's Income Statement
Miragen Therapeutics Inc 's second quarter 2019 Revenue $ 0.88 millions Quarterly MGEN's Income Statement


MGEN Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - - 578.38 % -54.39 %
3rd Quarter September - -80.68 % -22.92 % 301.68 %
2nd Quarter June 255 % 25.71 % -48.94 % -26.99 %
1st Quarter March - -72.11 % -56.88 % 126.39 %
FY (Year on Year)   - -59.3 % -56.03 % -


Back to MGEN Growth rate Comparisons >> Back to MGEN Growth rate Comparisons >>


Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #16
Healthcare Sector #250
Overall #1221

Revenue Y/Y Growth Statistics
High Average Low
279.71 % 20.45 % -56.27 %
(Jun 30 2018)   (Dec 31 2015)
Revenue second quarter 2020 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #16
Healthcare Sector #250
Overall #1221
Revenue Y/Y Growth Statistics
High Average Low
279.71 % 20.45 % -56.27 %
(Jun 30 2018)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Miragen Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
575.81 % 26.95 % -100 %
(Jun 30 2019)  


MGEN's II. Quarter Q/Q Revenue Comment
Miragen Therapeutics Inc achieved in the II. Quarter 2020 above company average sequential Revenue doubling of 255%, to $ 0.28 millions, from $0.08 millions in the first quarter.
MGEN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry Miragen Therapeutics Inc achieved highest sequential Revenue growth. While Miragen Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 121.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #44
Overall #121
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #0
Healthcare Sector #44
Overall #121
Revenue Q/Q Growth Statistics
High Average Low
575.81 % 26.95 % -100 %
(Jun 30 2019)  


MGEN's II. Quarter Q/Q Revenue Comment
Miragen Therapeutics Inc achieved in the II. Quarter 2020 above company average sequential Revenue doubling of 255%, to $ 0.28 millions, from $0.08 millions in the first quarter.
MGEN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry Miragen Therapeutics Inc achieved highest sequential Revenue growth. While Miragen Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 121.


Miragen Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)
Cumulative Revenue 12 Months Ending $ 0.00 $ 4.26 $ 4.46 $ 4.06 $ 4.31
Y / Y Revenue Growth (TTM) - 7.12 % -46.8 % -55.43 % -56.01 %
Year on Year Revenue Growth Overall Ranking # 3928 # 3518 # 3501 # 941 # 3896
Seqeuential Revenue Change (TTM) - -4.57 % 9.96 % -5.78 % 8.35 %
Seq. Revenue Growth (TTM) Overall Ranking # 1221 # 1090 # 1088 # 1991 # 440


Cumulative Revenue growth Comment
Miragen Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2020, compare to Revenue of $ 4 millions a year ago.

In the Healthcare sector 550 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3518 to 3928.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 16
Healthcare Sector # 551
Overall # 3928

Revenue TTM Y/Y Growth Statistics
High Average Low
279.71 %
 20.45 %
-56.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 250
S&P 500 # 1221
Cumulative Revenue growth Comment
Miragen Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2020, compare to Revenue of $ 4 millions a year ago.

In the Healthcare sector 550 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3518 to 3928.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 16
Healthcare Sector # 551
Overall # 3928

Revenue TTM Y/Y Growth Statistics
High Average Low
279.71 %
20.45 %
-56.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 250
S&P 500 # 1221




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MGEN's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Miragen Therapeutics Inc Revenue Growth Rates (MGEN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.